3 results about "Actin" patented technology

The present invention relates to an adeno-associated virus (AAV) vector comprising in the 5' to 3' direction: a first AAV2 ITR sequence; a CMV enhancer sequence; a chicken β-actin promoter sequence; a nucleic acid sequence encoding an apolipoprotein 2 (APOE2) polypeptide comprising a Christchurch mutation; a polyA sequence; and a second AAV2 ITR sequence.

The present invention relates to a biomarker for measuring anticancer drug resistance comprising a gene expressed in a group of cancer cells, wherein the gene releases an anticancer drug that has penetrated into the group of cancer cells to the outside of the group of cancer cells, wherein the gene comprises a gene selected from the group consisting of ABCG1, p-STAT3, STAT3, p-AKT, AKT, p-ERK, ERK, β-actin, ACTA2, GAS6, FAP, PDPN, COL1A1, AXL, and combinations thereof.

This invention belongs to the field of parasite detection technology, specifically relating to a lyophilized PCR kit for detecting Clonorchis sinensis in fecal samples. The lyophilized PCR kit of this invention includes a lyophilized reaction powder, a positive control, a negative control, and a reconstitution solvent. The lyophilized reaction powder is prepared by freeze-drying a reaction solution containing the following components: (a) a first primer pair and a first probe for detecting the Clonorchis sinensis COX1 gene; (b) a second primer pair and a second probe for detecting the human genomic actin (ACT) gene; (c) PCR reaction components: including hot-start Taq DNA polymerase, dNTPs, and a buffer system; and (d) a lyophilization protectant. This invention targets the Clonorchis sinensis-specific COX1 gene and uses PCR amplification technology to detect fecal samples, accurately identifying Clonorchis sinensis nucleic acid and effectively avoiding cross-reactions with other parasites and intestinal flora. The detection specificity and sensitivity are significantly improved, and the repeatability and stability are excellent.